Testosterone, Urethral Vascularity, and Urethral Stricture Disease: A Review

Urethral stricture disease is one of the oldest described urologic pathologies and urethroplasty is associated with high success rates. Many urethral strictures are thought to arise from iatrogenic injury or radiation therapy which can create ischemic insults to the urethra. In developed countries, most urethral strictures are idiopathic; therefore, much is still unknown about the etiology and pathogenesis of this disease. Testosterone is known to mediate vasculogenesis through vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1α$\alpha$ (HIF-1$\alpha$) pathways in various organs. Recently, testosterone has been shown to mediate urethral vasculogenesis. In the setting of testosterone deficiency, androgen supplementation can improve urethral vascularity. Further, there appears to be a high incidence of testosterone deficiency in men with urethral strictures. Despite many advances in our understanding of testosterone’s association with the urethra over the past few years, there remains much to be learned about the mechanism of testosterone on urethral stricture etiology and whether testosterone deficiency and supplementation impact urethral reconstruction outcomes.

urethral stricture; testosterone; testosterone deficiency; vasculogenesis

[1] Attwater HL. The History of Urethral Stricture. British Journal of Urology. 1943; 15: 39–51.

[2] Viers BR, Pagliara TJ, Rew CA, Folgosa Cooley L, Shiang CY, Scott JM, et al. Characteristics of Idiopathic Urethral Strictures: A Link to Remote Perineal Trauma? Urology. 2017; 110: 228–233.

[3] Fenton AS, Morey AF, Aviles R, Garcia CR. Anterior ure-thral strictures: etiology and characteristics. Urology. 2005; 65: 1055–1058.

[4] Lumen N, Hoebeke P, Willemsen P, De Troyer B, Pieters R, Oosterlinck W. Etiology of Urethral Stricture Disease in the 21st Century. Journal of Urology. 2009; 182: 983–987.

[5] Wessells H, Angermeier KW, Elliott S, Gonzalez CM, Kodama R, Peterson AC, et al. Male Urethral Stricture: American Uro-logical Association Guideline. Journal of Urology. 2017; 197: 182–190.

[6] Death AK, McGrath KC, Sader MA, Nakhla S, Jessup W, Han-delsman DJ, et al. Dihydrotestosterone promotes vascular cell adhesion molecule-1 expression in male human endothelial cells via a nuclear factor- kappaB-dependent pathway. Endocrinol-ogy. 2004; 145: 1889–1897.

[7] Sieveking DP, Lim P, Chow RW, Dunn LL, Bao S, McGrath KC, et al. A sex-specific role for androgens in angiogenesis. Journal of Experimental Medicine. 2010; 207: 345–352.

[8] Chen Y, Fu L, Han Y, Teng Y, Sun J, Xie R, et al. Testosterone replacement therapy promotes angiogenesis after acute myocar-dial infarction by enhancing expression of cytokines HIF-1a, SDF-1a and VEGF. European Journal of Pharmacology. 2012; 684: 116–124.

[9] Yucel S, Cavalcanti AG, Desouza A, Wang Z, Baskin LS. The ef-fect of oestrogen and testosterone on the urethral seam of the de-veloping male mouse genital tubercle. BJU International. 2003; 92: 1016–1021.

[10] Immergut M, Boldus R, Yannone E, Bunge R, Flocks R. The Lo-cal Application of Testosterone Cream to the Prepubertal Phal-lus. Journal of Urology. 1971; 105: 905–906.

[11] Husmann DA. Microphallic hypospadias–the use of human chorionic gonadotropin and testosterone before surgical repair. The Journal of Urology. 1999; 162: 1440–1441.

[12] Kaya C, Bektic J, Radmayr C, Schwentner C, Bartsch G, Oswald J. The efficacy of dihydrotestosterone transdermal gel before pri-mary hypospadias surgery: a prospective, controlled, random-ized study. The Journal of Urology. 2008; 179: 684–688.

[13] Nerli RB, Koura A, Prabha V, Reddy M. Comparison of topi-cal versus parenteral testosterone in children with microphallic hypospadias. Pediatric Surgery International. 2009; 25: 57–59.

[14] Bastos AN, Oliveira LRS, Ferrarez CEPF, de Figueiredo AA, Favorito LA, Bastos Netto JM. Structural study of prepuce in hypospadias–does topical treatment with testosterone produce alterations in prepuce vascularization? The Journal of Urology. 2011; 185: 2474–2478.

[15] Gearhart JP, Linhard HR, Berkovitz GD, Jeffs RD, Brown TR. Androgen receptor levels and 5 alpha-reductase activities in preputial skin and chordee tissue of boys with isolated hypospa-dias. The Journal of Urology. 1988; 140: 1243–1246.

[16] Snodgrass W, Bush NC. Re-operative urethroplasty after failed hypospadias repair: how prior surgery impacts risk for addi-tional complications. Journal of Pediatric Urology. 2017; 13: 289. e1–289.e6.

[17] Rynja SP, de Jong TPVM, Bosch JLHR, de Kort LMO. Testos-terone prior to hypospadias repair: Postoperative complication rates and long-term cosmetic results, penile length and body height. Journal of Pediatric Urology. 2018; 14: 31.e1–31.e8.

[18] Hofer MD, Morey AF, Sheth K, Tausch TJ, Siegel J, Cordon BH, et al. Low Serum Testosterone Level Predisposes to Artificial Urinary Sphincter Cuff Erosion. Urology. 2016; 97: 245–249.

[19] Wolfe AR, Ortiz NM, Baumgarten AS, VanDyke ME, West ML, Dropkin BM, et al. Most men with artificial urinary sphincter cuff erosion have low serum testosterone levels. Neurourology and Urodynamics. 2021; 40: 1035–1041.

[20] Hoy NY, Rourke KF. Artificial Urinary Sphincter Outcomes in the “Fragile Urethra”. Urology. 2015; 86: 618–624.

[21] Raj GV, Peterson AC, Toh KL, Webster GD. Outcomes follow-ing revisions and secondary implantation of the artificial urinary sphincter. Journal of Urology. 2005; 173: 1242–1245.

[22] Walsh IK, Williams SG, Mahendra V, Nambirajan T, Stone AR. Artificial urinary sphincter implantation in the irradiated patient: safety, efficacy and satisfaction. BJU international. 2002; 89: 364–368.

[23] Hofer MD, Kapur P, Cordon BH, Hamoun F, Russell D, Scott JM, et al. Decreased Periurethral Vascularity via an Androgen Receptor-mediated Process: Pilot Study in Urethral Stricture Tissue. Urology. 2017; 105: 175–180.

[24] Levy A, Browne B, Fredrick A, Stensland K, Bennett J, Sullivan T, et al. Insights into the Pathophysiology of Urethral Stricture Disease due to Lichen Sclerosus: Comparison of Pathological Markers in Lichen Sclerosus Induced Strictures vs Nonlichen Sclerosus Induced Stricture. The Journal of Urology. 2019; 201: 1158–1162.

[25] Spencer J, Mahon J, Daugherty M, Chang-Kit L, Blakely S, Mc-Cullough A, et al. Hypoandrogenism is Prevalent in Males with Urethral Stricture Disease and is Associated with Longer Stric-tures. Urology. 2018; 114: 218–223.

[26] Sabio Bonilla A, Jimenez A, Vila BP, Vicente Prados FJ, Puche SI. Low Serum Testosterone is Significantly More Frequent in Patients Diagnosed with Anterior Urethral Stricture. A Case-Control Study. Journal of Urology. 2021; 206: E23–E24.

[27] Yura EM, Bury MI, Chan Y, Morey AF, Sharma AK, Hofer MD. Reversing Urethral Hypovascularity through Testosterone and Estrogen Supplementation. Urology. 2020; 146: 242–247.

[28] Yura Gerbie E, Bury MI, Chan YY, Morey AF, Sharma AK, Hofer MD. Testosterone and Estrogen Repletion in a Hy-pogonadal Environment Improves Post-operative Angiogenesis. Urology. 2021; 152: 9.e1–9.e6.

[29] Nilsen OJ, Holm HV, Ekerhult TO, Lindqvist K, Grabowska B, Persson B, et al. To Transect or Not Transect: Results from the Scandinavian Urethroplasty Study, A Multicentre Randomized Study of Bulbar Urethroplasty Comparing Excision and Primary Anastomosis Versus Buccal Mucosal Grafting. European Urol-ogy. 2022. (in press)